Collectively, these studies were designed to determine whether simultaneous proteostasis disruption, PD-L1 inhibition, and TLR7 activation could reprogram the TAM-dominated, immunosuppressive TME into an immune-permissive environment, providing mechanistic and translational insights for combinatorial immunotherapy in MSS CRC (Scheme 1). The gene discussed is CD274; the disease is colorectal carcinoma.